Semax 10 mg

Compound profile

Semax: compound profile, literature landscape and handling notes

Where Semax came from

Semax comes out of a specific idea in peptide pharmacology that is worth reconstructing before the compound makes sense.

Adrenocorticotropic hormone is a 39-residue pituitary peptide whose canonical job is to act on the adrenal cortex through the melanocortin-2 receptor and drive corticosteroid synthesis. From the 1960s onward, a body of work most prominently associated with de Wied reported that short fragments cut from the middle of that hormone retained activity on learning and avoidance behavior in rats while having little or no effect on adrenal steroid output. ACTH(4-10) became the reference fragment. If that observation holds, the hormone carries two separable pharmacologies in one chain: an endocrine one requiring a specific receptor, and a behavioral one that apparently does not share the same structural requirements. Nothing about that is obvious, and it remains the most interesting claim attached to this family of peptides.

The design goal follows directly. If the behavioral fragment is separable from the steroidogenic activity, a compound built from the fragment alone should carry the first property and not the second, removing the endocrine consequence that would otherwise dominate any experiment. Semax is that reasoning taken one step further: rather than using ACTH(4-10) entire, it uses the shorter ACTH(4-7) and replaces the remainder with a stabilizing extension.

The extension is where the second history enters. From the 1980s onward the Institute of Molecular Genetics of the Russian Academy of Sciences, in work associated with Ashmarin and colleagues, pursued a general strategy for making short regulatory peptides survive long enough in a whole animal to be studied: cap the C-terminus with proline-glycine-proline, a motif borrowed from the endogenous glyprolines. Selank is that same strategy applied to tuftsin. Semax is it applied to an ACTH fragment, and the two compounds are siblings by method rather than by chemistry.

Two consequences follow for a reader working in English. Most primary work appeared in Russian-language journals, many not indexed in the databases searched by default, and English-language secondary literature has filled that gap with reviews that are then cited by further reviews. A reference list that looks broad often narrows to a handful of original reports. Semax also has a regulatory and clinical history inside one jurisdiction with no counterpart elsewhere. That is a factual statement about how one country's authorities have classified a substance. It is not evidence about the molecule and has no bearing on bench work.

Reading the structure of Semax

The sequence, formula and mass for this listing are printed in the specification table further down this page rather than restated here. What repays attention is what each residue is doing, because Semax is a compound where two different numbering systems are in play at once and most of the confusion about it comes from mixing them up.

In its own numbering the peptide runs methionine, glutamate, histidine, phenylalanine, proline, glycine, proline. In the numbering of the parent hormone, those first four residues are positions 4, 5, 6 and 7 of adrenocorticotropic hormone. That double numbering matters immediately, because the melanocortin message sequence, the four-residue motif His-Phe-Arg-Trp that melanocortin receptors actually read, sits at ACTH(6-9). Semax contains ACTH 6 and 7, histidine and phenylalanine, and stops there. The arginine and tryptophan that complete the motif are simply absent, replaced by proline-glycine-proline.

This is the structural fact that governs how Semax should be described. It overlaps the start of the melanocortin message sequence without containing it. A compound holding two residues of a four-residue recognition motif, with the remaining two swapped for a conformationally rigid proline-rich cap, is not a straightforward melanocortin receptor agonist, and the published record does not support treating it as one. This is the mirror image of the situation with KPV, which is what remains of alpha-MSH when the message core is deleted from the middle; Semax is what remains when the message core is truncated partway through from the C-terminal side. Both are melanocortin-adjacent and neither is a melanocortin ligand in the sense that PT-141 is.

The rest of the structure is unmodified L-amino acids. There is no acylation, no non-proteinogenic residue, no disulfide, and in the usual commercial form no C-terminal amidation. Everything the molecule does structurally comes from residue choice.

Two proteolytic details are worth noting because they are unusually clean. There is no lysine and no arginine anywhere in the chain, so Semax is not a trypsin substrate at all. Phenylalanine would normally make the chain a chymotrypsin substrate, but phenylalanine sits immediately before a proline, and proline in the following position blocks that cleavage. The chain interior is therefore fairly inhospitable to the two most common endopeptidases.

The proline-glycine-proline tail is the deliberate part. Carboxypeptidases handle a proline-rich terminus poorly, so the tail slows trimming inward from the C-terminus. Be precise about the limit: it does nothing for the amino end, where an exposed methionine is an ordinary aminopeptidase substrate, and it offers no protection against prolyl-specific peptidases, which are if anything well suited to a sequence like this. The stabilization is real, and it is one-sided.

The target and the pathway in more detail

Semax has no confirmed high-affinity receptor. There is no cloned target, no accepted binding curve for the intact heptapeptide, and no antagonist that reverses its reported effects in a way establishing receptor mediation. Every mechanism in the published record is downstream of something unidentified, and the word modulator, ubiquitous in secondary descriptions, is doing the work a named target would otherwise do.

The melanocortin question is the first to close off, because it is the most tempting wrong answer. The parent hormone is a melanocortin, the melanocortin receptors are well characterized, and it would be tidy if the fragment engaged them. It does not follow. The receptors read His-Phe-Arg-Trp, and Semax carries only the first half of that motif with the second half replaced. Fragments of this length are not reported to bind melanocortin receptors with affinity that would make receptor mediation a plausible account, and the original ACTH-fragment work was framed from the outset as activity dissociated from the classical endocrine receptor. Semax is best understood as a peptide whose parent is a melanocortin and whose own pharmacology is not melanocortin pharmacology.

What is actually reported falls into three threads. The most cited is neurotrophic: increased expression of brain-derived neurotrophic factor and nerve growth factor, and of their receptors, in rodent brain tissue, most often hippocampus, measured by transcript abundance and protein-level assays hours after exposure. This is the finding that carries almost all of the compound's mechanistic reputation, and it needs a caveat stated plainly. An increase in the expression of a neurotrophin is a transcriptional readout, not a target identification. It tells you the cell responded; it does not tell you what the peptide bound. Direct receptor engagement produces that pattern, but so does an indirect signaling cascade, a stress response, a systemic effect fed back into the tissue, and a number of frankly nonspecific perturbations. Neurotrophin induction is one of the least selective readouts in this area of biology, which is exactly why it is a poor basis for a mechanism claim.

The second thread is monoaminergic: reported changes in dopaminergic and serotonergic activity and turnover in rodent brain regions. These are neurochemical measurements, generally of tissue content and metabolite ratios rather than release at a defined synapse, and they place the compound in a system rather than identifying where it acts.

The third is enzymatic, and it is the most testable. Semax has been reported to inhibit the enzymes that degrade enkephalins, which would prolong the lifetime of an endogenous ligand rather than substituting for one. That is a different class of claim from receptor agonism, it can be examined in a cell-free system, and it does not require a receptor at all.

What the published literature on Semax actually measures

The Semax record sorts into recognizable groups, and knowing which one a citation belongs to determines how much weight it can carry.

The largest by volume is rodent behavioral pharmacology from Russian laboratories, much of it running from the 1980s to the 2000s. These are avoidance paradigms, maze work, open field measurements and comparisons against reference compounds run in the same experiments. What they measure are behavioral endpoints in animals under stated conditions. A large fraction predate current conventions on reporting randomization, blinding and sample-size justification, and many appeared in journals whose review process is not documented in English. They are evidence; they are evidence whose provenance the reader has to know.

The second group is molecular, and it is the most accessible in English. Microarray, quantitative polymerase chain reaction and immunoassay work in rat brain tissue reporting changes in neurotrophin and neurotrophin-receptor expression, in immediate-early genes, and across immune and vascular gene sets. This is the part a bench researcher can actually reason about, because the readouts are concrete and the platforms are reproducible in principle.

The third is preclinical ischemia modeling: focal ischemia in rodents with infarct volume, histology and animal behavioral scoring as endpoints, often combined with the gene-expression work above. These studies measure what happens in an animal model. Extrapolation past that is the reader's addition, not the paper's finding.

The fourth is peptide chemistry and metabolism: how quickly the intact heptapeptide disappears in plasma or tissue preparations, what fragments are generated, and which enzymes are responsible. This is the literature that supports the tail's design rationale and the literature anyone planning an incubation should read before the pharmacology.

The fifth is the enkephalin-degrading-enzyme enzymology, small but focused, and the only thread that describes an effect measurable outside a cell.

The sixth is clinical reporting in Russian neurological and psychiatric journals. Whatever its standing in its own context, it is not a bench reference. It does not characterize the molecule and it does not belong in the methods section of an in vitro protocol.

A seventh category deserves naming because it is so routinely mistaken for the literature itself: the English-language narrative review that summarizes the Russian work without reproducing its data, and the vendor page that summarizes the review. Most freely available descriptions of Semax descend from that chain, and the descent is usually invisible in the citation.

Where the Semax literature is thin or frequently misread

The weakness in the Semax record is not primarily that it is small. It is that it is hard to audit, and that several of its most repeated claims are stronger in restatement than in the original.

The first problem is concentration of authorship. A large share of the mechanistic and behavioral work traces to one institute and its immediate collaborators. Single-group findings are not wrong for being single-group, but they have not been through the replication that would let a careful reader treat them as settled, and the English review literature rarely flags how narrow the base is. Compounding this, the language barrier makes checking an original report impractical, so a paraphrase becomes the working source and the experimental conditions that determine whether two reports agree get lost in transit.

The second is the use of a regulatory fact as an evidence claim. That a substance has been used clinically within one country is a statement about that country's regulatory history. It is regularly deployed as though it demonstrated efficacy, sometimes with the implication that approval elsewhere is a formality not yet completed. Repeating the fact of approval adds no data. Treat it as jurisdiction information and nothing more.

The third is the shape of the clinical literature itself. The reports are generally small, frequently unblinded or with blinding not described, often lack a placebo comparison, and have rarely been replicated by groups outside the originating research community. Trials with those characteristics are hypothesis-generating in any field, and the absence of independent replication is a real gap rather than an administrative detail.

The fourth is the neurotrophin over-read already described. The step from an observed increase in expression to a mechanism is routinely made without the intermediate evidence, and without noting that the readout is downstream and nonspecific.

The fifth is nomenclature, and it is the most practically dangerous. Semax, N-acetyl-Semax and N-acetyl-Semax-amide are three different molecules marketed under near-identical names and discussed interchangeably in secondary sources. They differ in chemistry and in expected stability at the amino terminus, and in nothing about how they are described. Claims and material are both routinely transferred between them.

The sixth is the unstated assumption that the intact heptapeptide reaches central tissue in the form it was applied. Given how quickly short peptides are trimmed, a study reporting a central effect has not shown that the intact molecule was the species present.

How Semax behaves in solution

Semax is a small, unmodified, extremely hydrophilic peptide whose solution behavior is dominated by two residues: the methionine at the amino terminus and the histidine in the middle.

Solubility is not an issue. There is no lipophilic chain and no hydrophobic face to drive self-association, so none of the higher-order assembly that complicates acylated analogs occurs; it dissolves in water readily and completely.

Oxidation is the dominant chemical liability, and its position is what makes it consequential. Methionine is the most readily oxidized proteinogenic residue, converting to the sulfoxide under ordinary handling, promoted by dissolved oxygen, trace transition metals and light, and to the sulfone under harsher conditions. In many peptides the methionine is interior and its oxidation is a modest perturbation. Here it is residue one, so the oxidized species carries altered polarity at the most exposed end of the chain and an altered presentation to aminopeptidases. It should be treated as the default degradation route rather than an afterthought.

Histidine gives the molecule pH-dependent charge. Its imidazole side chain titrates near the middle of the ordinary buffer range, so between mildly acidic and neutral conditions the net charge changes without anything else about the sample changing. With a glutamate side chain and free C-terminal carboxyl as well, the result is a near-neutral, weakly amphoteric molecule rather than the strongly cationic behavior seen with Selank. Adsorption still occurs at low concentration and high surface-to-volume ratio, but the electrostatic argument that predicts it for a cationic peptide does not apply here, so losses are less predictable rather than smaller.

Backbone chemistry is otherwise favorable. There is no asparagine or glutamine, so the deamidation route that governs many peptides is unavailable, and no cysteine, so disulfide scrambling is not a concern. One cascade is worth knowing: if aminopeptidase activity removes the N-terminal methionine, the newly exposed glutamate can cyclize to pyroglutamate, a well-described route for peptides with glutamate at the amino terminus, giving a blocked terminus and a distinct species.

The two prolines interconvert slowly between cis and trans amide configurations, which can broaden or split a chromatographic peak without a second species. The trap specific to this compound is that degraded solution looks normal: oxidation produces no turbidity and no color, so appearance is close to useless as an integrity check. The storage statement in the specification table is the product record; the documentation supplied with the lot governs.

Analytical notes specific to Semax

Semax presents a detection problem, an impurity problem and an identity problem, in that order.

Detection first. There is no tryptophan and no tyrosine anywhere in the sequence, so the absorbance maximum near 280 nanometers that most peptide work relies on does not exist. Phenylalanine absorbs weakly around 255 to 260 nanometers and histidine below that, but neither supports a routine quantitative method. Detection therefore sits at low ultraviolet, around 214 nanometers, where response comes from the peptide bond itself and scales roughly with the number of amide bonds. A short fragment gives a peak much smaller than its molar share, so area percent from a single low-ultraviolet wavelength systematically understates truncation products.

The impurity family that matters most is oxidation. The sulfoxide differs from the parent by 16 mass units and the sulfone by 32, and on reversed phase the more polar sulfoxide elutes earlier, typically as a shoulder or a partially resolved satellite ahead of the main peak. Because the methionine is terminal and exposed, this family is the expected impurity profile rather than a sign of mishandling, and a method that does not resolve the early-eluting region misses the thing most likely to be there.

The identity problem is the acetylated variants, and it is the one worth worrying about. N-acetylation of the amino terminus adds 42 mass units; amidation of the C-terminus removes roughly one. Those are large, unambiguous differences for any mass spectrometer, so telling the three apart is trivial once someone looks. The risk is not analytical difficulty, it is that nobody looks. The three are sold and discussed under nearly the same name, and a mislabeled or substituted lot is a live possibility rather than a theoretical one. Intact mass resolves it immediately, which makes it a cheap check to insist on.

Two further notes. At seven residues, losing one amino acid is a large fractional change in mass and stands out clearly, unlike a long peptide where a deletion hides in the isotope envelope; but intact mass cannot order residues, so tandem mass spectrometry giving a sequence ladder is what distinguishes Semax from a rearranged peptide of identical composition. And because the histidine makes retention and peak shape pH-sensitive, a separation at a different mobile-phase pH is a more informative second method than the same method with a different gradient.

Compounds researchers confuse with Semax

Questions specific to Semax